U.S. market Closed. Opens in 11 hours 53 minutes

NAVB | Navidea Biopharmaceuticals, Inc. Stock Fundamentals

(Stock Exchange: AMEX)
Analyzing fundamentals for NAVB we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is poor, Growth is bad and Health is frighteningly weak.

Valuation (17%)

Company Industry
P/E Ratio (TTM) 0.03 -16.22
PEG Ratio (TTM) 0.00 -1.41
P/S Ratio (TTM) N/A 48.82
P/B Ratio (TTM) -0.03 21.13
P/FCF Ratio (TTM) -0.01 9.38
Price to 5YR AVG Earnings Ratio 0.00 -0.21
Price to 5YR AVG FCF Ratio -0.01 -7.10

Profitability (50%)

Company Industry
ROA (TTM) 52.34% -3.10%
ROE (TTM) -63.06% 24.21%
Net Profit Margin (TTM) N/A -1,069.78%
ROIC 5YR AVG 400.92% 16.50%

Growth (42%)

4QTR AVG 3YR AVG 5YR AVG
EPS 144.92% -6.51% -11.18%
Revenue -47.97% 1,054.55% 606.82%
Net Income 205.75% -28.87% -28.72%
Cash Flow 13.03% -132.98% -82.38%

Health (7%)

Company Industry
Current Ratio (TTM) 0.56 5.75
Quick Ratio (TTM) 0.51 5.47
D/E Ratio (TTM) -0.38 -15.13
Interest Coverage (TTM) -9.01 3.59
Piotroski F-Score 2 5
Altman Z-Score N/A 13.47
LTL to 5YR AVG FCF -0.28 0.20
Shares Outstanding Growth 5YR AVG 32.63% 118.86%
An error has occurred. This application may no longer respond until reloaded. Reload 🗙